Jade Biosciences, Inc.
JBIO
$24.71
$0.903.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.07M | 24.45M | 20.42M | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 164.74M | 133.60M | 113.54M | -- | -- |
| Operating Income | -164.74M | -133.60M | -113.54M | -- | -- |
| Income Before Tax | -153.15M | -129.54M | -127.35M | -- | -- |
| Income Tax Expenses | 89.00K | 74.00K | 58.00K | -- | -- |
| Earnings from Continuing Operations | -153.24 | -129.61 | -127.41 | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.24M | -129.61M | -127.41M | -- | -- |
| EBIT | -164.74M | -133.60M | -113.54M | -- | -- |
| EBITDA | -164.70M | -133.57M | -90.13M | -- | -- |
| EPS Basic | -2.31 | -2.41 | -10.71 | -- | -- |
| Normalized Basic EPS | -1.77 | -1.77 | -5.48 | -- | -- |
| EPS Diluted | -2.31 | -2.41 | -10.71 | -- | -- |
| Normalized Diluted EPS | -1.77 | -1.77 | -5.48 | -- | -- |
| Average Basic Shares Outstanding | 212.40M | 179.78M | 125.44M | -- | -- |
| Average Diluted Shares Outstanding | 212.40M | 179.78M | 125.44M | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |